Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Cash from Financing Activities for 10 consecutive years, with $394.2 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 13285.13% to $394.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $478.0 million through Dec 2025, up 19.8% year-over-year, with the annual reading at $478.0 million for FY2025, 19.8% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $394.2 million at Ultragenyx Pharmaceutical, up from $2000.0 in the prior quarter.
  • The five-year high for Cash from Financing Activities was $491.9 million in Q3 2022, with the low at -$722000.0 in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $94.2 million, with a median of $11.9 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 17459.4% in 2023, while the deepest fall reached 144.79% in 2023.
  • Over 5 years, Cash from Financing Activities stood at $85.7 million in 2021, then plummeted by 97.8% to $1.9 million in 2022, then soared by 17459.4% to $330.5 million in 2023, then tumbled by 99.11% to $2.9 million in 2024, then soared by 13285.13% to $394.2 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $394.2 million, $2000.0, and $83.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.